关于治疗表皮生长因子受体突变非小细胞肺癌的最新情况
Jinyong Kim1, Sehhoon Park1, Bo Mi Ku2
1Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Seoul, Republic of Korea.
本综述详细介绍了用表皮生长因子受体 (EGFR) 突变治疗非小细胞肺癌 (NSCLC) 的进展. 精准医学和克服耐药性是优化EGFR突变NSCLC患者治疗结果的关键.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 具有表皮生长因子受体 (EGFR) 突变的非小细胞肺癌 (NSCLC) 提出了独特的治疗挑战.
- 第一代EGFR氨酸激酶抑制剂 (TKI) 证明了最初的疗效,推动了精确瘤学领域的发展.
研究的目的:
- 提供关于EGFR突变NSCLC的当前和新兴治疗方法的全面更新.
- 突出克服针对EGFR向疗法的获得性耐药性的策略.
- 讨论EGFR技术知识的作用在NSCLC的各个阶段.
主要方法:
- 对EGFR突变NSCLC治疗的当前文献的综述.
- 分析精准医学和向治疗的进展.
- 检查耐药机制和新的治疗方法.
主要成果:
- 第三代EGFRTKI是目前高级NSCLC的第一线护理标准.
- 结合第三代EGFRTKI与化疗或阿米万塔马布的结合,可以改善无进展生存率.
- 对于早期NSCLC,EGFR TKIs正在经手术前和新辅助环境中进行探索.
结论:
- 对EGFRTKI的获得性耐药性是复杂而异质的,需要个性化治疗策略.
- 对EGFR突变NSCLC的治疗环境是动态的,需要不断调整治疗方法.
- 优化患者的治疗结果取决于针对个体耐药机制的量身定制策略.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Mitogens and the Cell Cycle
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment Resistant Cancers
